Compounds of formula (I) or pharmaceutically acceptable salts thereof are provided where at least one of R.sub.2 or R.sub.3 is not hydrogen. The compounds of the present invention are N-methyl-D-aspartate (NMDA) receptor antagonists and are useful in treating a variety of conditions present in a mammal that benefit from inhibiting the NMDA receptor.